OrthoPediatrics (KIDS)
(Delayed Data from NSDQ)
$31.95 USD
+0.73 (2.34%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $31.96 +0.01 (0.03%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth B Momentum D VGM
OrthoPediatrics (KIDS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$41.50 | $50.00 | $30.00 | 29.89% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for OrthoPediatrics comes to $41.50. The forecasts range from a low of $30.00 to a high of $50.00. The average price target represents an increase of 29.89% from the last closing price of $31.95.
Analyst Price Targets (6 )
Broker Rating
OrthoPediatrics currently has an average brokerage recommendation (ABR) of 1.50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.50 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, four are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 66.67% and 16.67% of all recommendations. A month ago, Strong Buy made up 66.67%, while Buy represented 16.67%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/KIDS.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/16/2024 | Needham & Company | Michael Matson | Moderate Buy | Moderate Buy |
8/6/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/16/2024 | Truist Securities | Richard Newitter | Not Available | Hold |
3/27/2024 | Piper Sandler | Matthew O'Brien | Strong Buy | Strong Buy |
3/7/2024 | JMP Securities | David L Turkaly | Strong Buy | Strong Buy |
1/7/2024 | BTIG | Ryan Zimmerman | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.50 |
ABR (Last week) | 1.50 |
# of Recs in ABR | 6 |
Average Target Price | $41.50 |
LT Growth Rate | NA |
Industry | Medical - Instruments |
Industry Rank by ABR | 73 of 253 |
Current Quarter EPS Est: | -0.19 |